Are Wegovy and Ozempic the same medication?
Wegovy and Ozempic are the same in one important way: both contain semaglutide, a GLP-1 receptor agonist. Semaglutide acts on GLP-1 receptors and can affect appetite, fullness, food intake and blood glucose regulation. Wegovy’s UK patient leaflet describes it as a medicine for weight loss and weight maintenance that acts on appetite receptors in the brain, while Ozempic’s UK patient leaflet describes it as a medicine for adults with type 2 diabetes. [1][5]
They are not interchangeable products. The brand, indication, dose range, clinical trial programme and prescribing decision are different. For weight-management searches, this distinction matters because Ozempic may be associated with weight loss, but Ozempic is not the UK semaglutide product designed and dosed as a weight-management medicine.
The main differences at a glance
|
Question
|
Wegovy
|
Ozempic
|
What this means
|
|
Active ingredient
|
Semaglutide.
|
Semaglutide.
|
Same active ingredient does not mean the same approved use or dose range.
|
|
Main UK treatment aim
|
Weight management, including weight loss and weight maintenance, alongside reduced-calorie diet and increased physical activity. [1][2]
|
Treatment of adults with type 2 diabetes when diet and exercise are not enough. [5]
|
Wegovy is the relevant semaglutide brand for weight-management evidence; Ozempic is primarily a diabetes medicine.
|
|
Usual dose path
|
Escalates from 0.25 mg weekly to 2.4 mg weekly. Product information also includes 7.2 mg weekly for selected adults with obesity if needed after 2.4 mg. [2][3][4]
|
Escalates from 0.25 mg weekly to 0.5 mg, 1 mg or 2 mg weekly for glycaemic control. Weekly doses above 2 mg are not recommended. [6]
|
The dose ladders are not equivalent. Ozempic 2 mg is not the same as Wegovy 2.4 mg or 7.2 mg.
|
|
Weight-loss evidence
|
The STEP weight-management trial programme studied semaglutide at weight-management doses with lifestyle intervention. [2][7]
|
Ozempic trials include body-weight changes in people with type 2 diabetes, but their main treatment aim is glycaemic control. [6]
|
Wegovy has the more relevant evidence base when the clinical aim is weight management.
|
|
Reader action
|
Suitability, dose and monitoring must be decided by a prescriber.
|
Suitability, dose and monitoring must be decided by a prescriber, especially where diabetes medicines are involved.
|
Do not choose between them based on weight-loss expectation alone.
|
How the doses compare
Both medicines start at a low dose to reduce the likelihood of gastrointestinal side effects, but their dose paths then diverge.
Wegovy dose schedule
- Weeks 1–4: 0.25 mg once weekly.
- Weeks 5–8: 0.5 mg once weekly.
- Weeks 9–12: 1 mg once weekly.
- Weeks 13–16: 1.7 mg once weekly.
- Maintenance dose for all indications: 2.4 mg once weekly.
- For adult weight management in patients with obesity, UK product information now includes 7.2 mg once weekly if needed after at least four weeks on 2.4 mg. This must be decided and prescribed clinically. [2][3][4]
The Wegovy SmPC also states that if significant gastrointestinal symptoms occur, dose escalation may need to be delayed or the dose lowered to the previous step until symptoms improve. This is one reason dose changes should not be made independently. [2][3]
Ozempic dose schedule
- Weeks 1–4: 0.25 mg once weekly.
- After four weeks: 0.5 mg once weekly.
- If needed for blood sugar control: 1 mg once weekly after at least four weeks on 0.5 mg.
- If needed for blood sugar control: 2 mg once weekly after at least four weeks on 1 mg.
- Ozempic 0.25 mg is not a maintenance dose, and weekly doses above 2 mg are not recommended in the Ozempic SmPC. [6]
There is no UK Ozempic dose schedule for weight loss. Queries such as “Ozempic 2.4 mg dose” or “Ozempic dosing for weight loss” usually reflect confusion between Ozempic and Wegovy. Wegovy is the semaglutide brand with the weight-management dose schedule.
Which is more effective for weight loss?
For weight management, Wegovy has the stronger and more relevant evidence base because it is the semaglutide product studied and dosed for weight loss and weight maintenance. That does not mean Wegovy is automatically suitable for every person, and it does not mean every patient will get trial-level results.
In STEP 1, adults with overweight or obesity who received semaglutide 2.4 mg once weekly plus lifestyle intervention had a mean body-weight change of -14.9% at 68 weeks, compared with -2.4% in the placebo group. [7]
The newer Wegovy 7.2 mg product information includes STEP UP data in adults with obesity. At 72 weeks, the listed change from baseline was -18.7% with semaglutide 7.2 mg, -15.6% with semaglutide 2.4 mg and -3.9% with placebo. A separate on-treatment analysis in the same product information estimated -20.7% with 7.2 mg, -17.5% with 2.4 mg and -2.4% with placebo. [3]
Ozempic diabetes trials also record weight reductions, but those trials were designed around type 2 diabetes outcomes. For example, the Ozempic 2 mg SmPC includes studies where semaglutide 0.5 mg and 1 mg reduced body weight in people with type 2 diabetes, but the clinical aim was glycaemic control, not obesity treatment. [6]
A fair answer is therefore: Wegovy is the more appropriate semaglutide comparison point for weight-management results; Ozempic may reduce weight in some people with type 2 diabetes, but it should not be treated as a like-for-like weight-loss version of Wegovy.
Why the same ingredient can produce different results
The active ingredient is only one part of the picture. Results can differ because of dose exposure, how slowly the dose is escalated, the patient population being treated, the aim of treatment, side-effect tolerance, adherence and the nutrition and activity plan used alongside the medicine.
Wegovy’s product information links use of the medicine with a reduced-calorie meal plan and increased physical activity. That does not mean weight loss is simply a matter of willpower. It means semaglutide is intended to sit inside a structured treatment plan that considers appetite, nutrition, side effects, medical history and monitoring. [1][2]
Side effects and safety: what needs attention
Because Wegovy and Ozempic both contain semaglutide, their safety considerations overlap. The most frequent adverse reactions listed for semaglutide at Wegovy weight-management doses are gastrointestinal, including nausea, diarrhoea, constipation and vomiting. These are most often reported during dose escalation. [2][3]
Do not take Wegovy and Ozempic together. Do not switch between them, restart after a break, skip doses deliberately, take extra doses or increase the dose without prescriber advice. This is especially important if you have diabetes, take insulin or sulfonylureas, have troublesome side effects, are planning pregnancy, are breastfeeding, or have a history of pancreatitis, gallbladder disease, significant stomach-emptying problems or diabetic eye disease.
Seek urgent medical help if you develop severe, persistent abdominal pain, with or without nausea and vomiting; symptoms of a severe allergic reaction such as swelling of the face, lips, tongue or throat or breathing difficulty; severe dehydration symptoms such as confusion, fainting, very little urine or being unable to keep fluids down; chest pain or fainting; sudden or rapidly worsening vision changes; or thoughts of self-harm. These symptoms should not be waited out at home.
|
Route
|
Examples
|
Why it matters
|
What to do
|
|
Monitor / self-manage
|
Mild nausea, mild constipation, mild diarrhoea, reduced appetite or temporary digestive discomfort during dose escalation that is improving.
|
These can be expected semaglutide side effects, but they still need monitoring so they do not become dehydration, poor nutrition or treatment-adherence problems.
|
Follow the advice from your prescriber. Keep fluids up, eat smaller plain meals if advised, avoid dose changes unless told, and raise symptoms at review.
|
|
Contact your prescriber / clinician
|
Persistent or worsening nausea, vomiting or diarrhoea; side effects affecting eating, drinking, work or sleep; low blood sugar symptoms if using diabetes medicines; missed-dose confusion; dose-escalation concerns; pregnancy or breastfeeding questions; eye changes in diabetes; palpitations or dizziness.
|
These may need dose adjustment, a delay in dose escalation, review of other medicines, diabetes monitoring, pregnancy advice or clinical judgement before the next dose.
|
Contact your prescriber, GP, pharmacist or diabetes team as appropriate. Do not take an extra dose or change schedule while waiting for advice.
|
|
Seek urgent medical help
|
Severe persistent abdominal pain, especially with nausea or vomiting; severe allergic symptoms; severe dehydration; chest pain, collapse or fainting; sudden or rapidly worsening vision loss; suicidal thoughts or risk of self-harm.
|
These could indicate pancreatitis, severe reaction, dehydration complications, cardiovascular symptoms, eye complications or immediate mental-health risk.
|
Seek urgent medical advice now. Use NHS 111, 999 or A&E depending on severity. If there is immediate danger of self-harm, call 999 or go to A&E.
|
Can you switch from Ozempic to Wegovy?
Some people may be moved from one semaglutide product to another, but this is a prescribing decision, not a simple brand swap. A prescriber needs to consider why the switch is being requested, the current dose, how long the person has been taking it, side effects, diabetes status, other medicines, pregnancy or breastfeeding, and any relevant safety history.
The two medicines should not be overlapped. If you are using Ozempic for type 2 diabetes, switching purely for weight loss could also affect diabetes monitoring and other medicines. If you are using semaglutide outside a standard pathway, the safest next step is to be open with your clinician about exactly what you have taken and when.
What to track before asking about dose, results or switching
Before asking whether a dose should change or whether Wegovy or Ozempic is “working”, it helps to have accurate information rather than relying on one weigh-in or a single week of appetite change.
- Your current medicine, dose, start date and dose-increase dates.
- Your weight trend over at least four weeks, not just the most recent reading.
- Changes in appetite, fullness, cravings and portion size.
- Side effects, including when they started and whether they worsened after a dose increase.
- Missed doses, delayed doses or any break in treatment.
- Other medicines, especially insulin, sulfonylureas, anticoagulants and any medicines affected by vomiting or poor intake.
- Hydration, constipation, diarrhoea or vomiting patterns.
- Any red-flag symptoms, pregnancy plans, breastfeeding, surgery plans or diabetic eye symptoms.
What happens if you stop semaglutide?
Weight regain is common after semaglutide is stopped. In the STEP 1 extension, participants who had previously received semaglutide regained 11.6 percentage points of lost weight during the year after treatment withdrawal, which the authors described as regaining about two-thirds of their prior weight loss. [8]
This does not mean everyone must stay on treatment indefinitely. It does mean stopping should be planned. A prescriber can help decide whether to continue, reduce, stop, switch or focus on maintenance support, based on results, side effects, safety and longer-term health aims.
